

Company Registration No. 07700799 (England and Wales)

HEALTH DATA INSIGHT C.I.C.
UNAUDITED ABBREVIATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2014

FRIDAY



A4GNN608

A07

25/09/2015

#310

COMPANIES HOUSE

HEALTH DATA INSIGHT C.I.C.

CONTENTS

	Page
Abbreviated balance sheet	1
Notes to the abbreviated accounts	2 - 3

HEALTH DATA INSIGHT C.I.C.

ABBREVIATED BALANCE SHEET

AS AT 31 DECEMBER 2014

	Notes	2014 £	£	2013 £	£
Fixed assets					
Tangible assets	2		7,109		7,505
Investments	2		30		30
			<u>7,139</u>		<u>7,535</u>
Current assets					
Debtors		92,833		59,972	
Cash at bank and in hand		126,548		101,400	
		<u>219,381</u>		<u>161,372</u>	
Creditors: amounts falling due within one year		<u>(34,572)</u>		<u>(31,207)</u>	
Net current assets			<u>184,809</u>		<u>130,165</u>
Total assets less current liabilities			<u>191,948</u>		<u>137,700</u>
Capital and reserves					
Called up share capital	3		2		2
Profit and loss account			191,946		137,698
			<u>191,948</u>		<u>137,700</u>
Shareholders' funds			<u>191,948</u>		<u>137,700</u>

For the financial year ended 31 December 2014 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies

Directors' responsibilities

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476,
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements

These abbreviated financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime

Approved by the Board for issue on 18 September 2015


Mrs H J Wilderspin
Director

Company Registration No 07700799

HEALTH DATA INSIGHT C.I.C.

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2014

1 Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

1.2 Compliance with accounting standards

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), which have been applied consistently (except as otherwise stated)

1.3 Turnover

Turnover represents amounts receivable for consultancy services net of VAT. In respect of contracts for on-going services, turnover represents the value of work done in the year, including estimates of amounts not invoiced.

1.4 Research and development

Research expenditure is written off to the profit and loss account in the year in which it is incurred. Development expenditure is written off in the same way unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit.

1.5 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Computer equipment	3 years on a straight line basis
Fixtures, fittings & equipment	20% on a reducing balance basis

1.6 Investments

Fixed asset investments are stated at cost less provision for diminution in value.

HEALTH DATA INSIGHT C.I.C.

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2014

2 Fixed assets

	Tangible assets	Investments	Total
	£	£	£
Cost			
At 1 January 2014	9,314	30	9,344
Additions	3,310	-	3,310
At 31 December 2014	12,624	30	12,654
Depreciation			
At 1 January 2014	1,809	-	1,809
Charge for the year	3,706	-	3,706
At 31 December 2014	5,515	-	5,515
Net book value			
At 31 December 2014	7,109	30	7,139
At 31 December 2013	7,505	30	7,535

Holdings of more than 20%

The company holds more than 20% of the share capital of the following companies

Company	Country of registration or incorporation	Shares held Class	%
Participating interests			
Coherence Data Limited	England and Wales	Ordinary	30.00

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows

	Capital and reserves	Profit/(loss) for the year
	2014	2014
	£	£
Principal activity		
Coherence Data Limited		
Other business support service activities not elsewhere classified	3,448	(721)

The results for Coherence Data Limited are for the year to 30 April 2015

3 Share capital	2014	2013
	£	£
Allotted, called up and fully paid		
2 Ordinary shares of £1 each	2	2

15/000116

CIC 34**Community Interest Company Report**

For official use
(Please leave blank)

*Please
complete in
typescript, or
in bold black
capitals*

**Company Name in
full**

Health Data Insight C I C

Company Number

07700799

Year Ending

31 December 2014

This template illustrates what the Regulator of Community Interest Companies considers to be best practice for completing a simplified community interest company report. All such reports must be delivered in accordance with section 34 of the Companies (Audit, Investigations and Community Enterprise) Act 2004 and contain the information required by Part 7 of the Community Interest Company Regulations 2005. For further guidance see chapter 8 of the Regulator's guidance notes and the alternate example provided for a more complex company with more detailed notes.

(N.B. A Filing Fee of £15 is payable on this document. Please enclose a cheque or postal order payable to Companies House)

PART 1 - GENERAL DESCRIPTION OF THE COMPANY'S ACTIVITIES AND IMPACT

In the space provided below, please insert a general account of the company's activities in the financial year to which the report relates, including a description of how they have benefited the community.

Health Data Insight (HDI) C I C was established in July 2011 to improve access to and understanding of health data and information to benefit healthcare delivery and outcomes.

During 2014, we have maintained our contracts of benefit to our core community and developed further new areas of business.

In our third full year of trading we continue to work with our Board to develop the business strategy for the company. We continue to benefit from expert advice on business planning, pricing, costing and now have established financial analysis of project costing, investment activities, overhead costs, cashflow and income projections.

Patients – we continue to receive funding from Cancer Research UK to support the development of a patient portal. This gives individual patients access to the data collected by the National Cancer Registration Service and allows them to contribute information on their care. The evaluation of the project has confirmed that the service is highly valued and (cont.)

(If applicable, please just state "A social audit report covering these points is attached")

(Please continue on separate continuation sheet if necessary)

PART 2 – CONSULTATION WITH STAKEHOLDERS – Please indicate who the company's stakeholders are, how the stakeholders have been consulted and what action, if any, has the company taken in response to feedback from its consultations? If there has been no consultation, this should be made clear

Stakeholders in the Company include

- Patients
- NHS and government organisations e g hospitals, clinical commissioning groups, Department of Health, Public Health England
- Healthcare Workers
- Royal Colleges
- Health research organisations
- Charities with an interest in health data
- Private companies e g pharmaceutical companies

Stakeholders have been consulted individually with face to face meetings, presentations and written proposals. In addition, for specific projects, stakeholder and focus groups have been used to advise on the development of the project e g patient portal while wider (cont)

(If applicable, please just state "A social audit report covering these points is attached")

PART 3 – DIRECTORS' REMUNERATION – if you have provided full details in your accounts you need not reproduce it here. Please clearly identify the information within the accounts and confirm that, "There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director's loss of office, which require to be disclosed" (See example with full notes) If no remuneration was received you must state that "no remuneration was received" below

There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director's loss of office, which require to be disclosed

PART 4 – TRANSFERS OF ASSETS OTHER THAN FOR FULL CONSIDERATION – Please insert full details of any transfers of assets other than for full consideration e g Donations to outside bodies. If this does not apply you must state that "no transfer of assets other than for full consideration has been made" below

No transfer of assets other than for full consideration has been made

(Please continue on separate continuation sheet if necessary)

PART 5 – SIGNATORY

The original report must be signed by a director or secretary of the company

Signed

H. W. Jones

Date

15/9/15

Office held (delete as appropriate) Director/Secretary

You do not have to give any contact information in the box opposite but if you do, it will help the Registrar of Companies to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record

Tel	
DX Number	DX Exchange

When you have completed and signed the form, please attach it to the accounts and send both forms by post to the Registrar of Companies at:

For companies registered in England and Wales: Companies House, Crown Way, Cardiff, CF14 3UZ
DX 33050 Cardiff

For companies registered in Scotland: Companies House, 4th Floor, Edinburgh Quay 2, 139
Fountainbridge, Edinburgh, EH3 9FF DX 235 Edinburgh or LP – 4 Edinburgh 2

For companies registered in Northern Ireland: Companies House, 2nd Floor, The Linenhall, 32-38
Linenhall Street, Belfast, BT2 8BG

CIC 34

CONTINUATION SHEET

*Please
complete in
typescript, or
in bold black
capitals.*

**Company Name in
full**

Health Data Insight C I C

Company Number

07700799

Year Ending

31 December 2014

PLEASE CLEARLY INDICATE THE PART YOU ARE CONTINUING HERE

PART 1 - GENERAL DESCRIPTION OF THE COMPANY'S ACTIVITIES AND IMPACT (cont)

we have expanded the range of tumour sites to include breast and prostate cancer We have identified a strategic partner and anticipate that this will allow us a rapid and significant expansion to a wider audience in the next year

Patients, clinicians and researchers – In partnership with CR-UK we developed a data visualization tool as part of the International Cancer Benchmarking Partnership This is a key international research project that is aimed at understanding why one year cancer survival for common cancer in England appears less good than elsewhere in the World Our work has created an online simulation environment to show the relative contribution of individual factors to overall survival calculations

Patients and clinicians – we continue to deliver the contract with the Royal College of Surgeons to provide the technical support for the data collection underpinning the Royal College of Surgeon's National Prostate Cancer Audit We have provided expert advice on the data set collection and managed the data collection arrangements with clinical teams across the country to ensure a robust information governance framework

Patients and clinicians – we have been sponsored by both Pfizer, Novartis and Merck Serona to collect data molecular testing data on cancer genes

We continue to use some of our revenue to fund the development of data presentation and interpretation tools that will others to interrogate and analyse our data These sophisticated computer programmes will permit the analysis of care pathways and outcomes on all cancer patients treated in England

CIC 34

CONTINUATION SHEET

*Please
complete in
typescript, or
in bold black
capitals*

**Company Name in
full**

Health Data Insight C I C

Company Number

07700799

Year Ending

31 December 2014

PLEASE CLEARLY INDICATE THE PART YOU ARE CONTINUING HERE

PART 2 – CONSULTATION WITH STAKEHOLDERS (cont)

stakeholder audiences have been engaged through speaking at public forums and conferences

We have provided expert input and managerial oversight to the Patient Reported Outcome Survey on cancer patients –including the development of a patient-centric website to support the survey

In partnership with CR-UK we have run focus groups of patients to help design patient information leaflets explaining why cancer data collection is so important

Action taken as a result of the consultations has been to tailor specific proposals to the needs of the stakeholder and funding for the C I C has been secured as a result